DLF Science Advisory Board Spotlight
Dan Lewis Foundation | Summer 2024

Stephen Mark Strittmatter, MD, PhD, earned his undergraduate degree from Harvard, and completed doctoral training at Johns Hopkins. His medical internship and neurology residency were at Massachusetts General Hospital. He joined the Yale faculty in 1993, and is now Chair and Professor of Neuroscience and Vincent Coates Professor of Neurology.  He is Director of the Kavli Institute for Neuroscience at Yale, the Yale Cellular Neuroscience, Neurodegeneration and Repair Program, the Yale Alzheimer Disease Research Center and the Yale Memory Disorders Clinic.


His work on developmental axonal guidance led to his discovery of a Nogo Receptor pathway critical for axonal re-growth after injury.  He showed that glia-derived inhibitors bind this receptor, activate RhoA and prevent neural repair.  He developed a soluble Nogo Receptor decoy protein that blocks the endogenous ligand-receptor interaction, promoting recovery from spinal cord injury and stroke. This therapeutic protein is now in clinical trials for patients with chronic spinal cord injury. Strittmatter has also translated discoveries in neurodegeneration to clinical approaches. Using innovative screens, he identified the roles of Prion Protein and metabotropic glutamate receptor 5 (mGluR5) as Aß oligomer receptors. He linked activation of these receptors to a pair of synaptic tyrosine kinases, the Tau-interacting Fyn and the AD risk gene PTK2B. Critically, this pathway contributes to synapse loss and memory deficits in preclinical models.  He subsequently identified a Fyn inhibitor which was tested in an AD clinical trial.  Strittmatter has developed additional methods for targeting this pathway with robust preclinical efficacy.  One approach uses novel mGluR5 silent allosteric modulators, which are now in clinical trials.


An author of over 280 original reports, Dr. Strittmatter has been recognized by the King Faisal International Prize in Medicine, Ameritec Award for Spinal Injury Research, McKnight Brain and Memory Disorders Award, Alzheimer Association Zenith Fellow Award, Senator Jacob Javits Award in the Neurosciences, and an NINDS Outstanding Investigator Award. 

Gloved hands hold a tablet showing medical data in a lab with blurred researchers in the background
By Dan Lewis Foundation July 24, 2026
ARPA-H, which stands for Advanced Research Projects Agency for Health, is an agency within the U.S. Department of Health and Human Services. One of its major projects is called the FRONT program which stands for Functional Repair of Neocortical Tissue .  The FRONT program focuses on repair and regeneration of the neocortex, the largest part of the brain. The neocortex is critical for many aspects of cognition and everyday functioning. The neocortex can be damaged in many ways including stroke, traumatic injury, and neurodegeneration, such as in Alzheimer's disease. Serious damage to the neocortex often causes individuals to be dependent on costly therapies or caregivers and can also lead to related health and medical problems. The FRONT program hopes to alter this pattern by using cutting-edge neurodevelopmental principles and stem cell technology to regenerate brain tissue and restore lost functions.
Lab technicians in blue gloves working with samples in a bright laboratory
By Hal Lewis July 24, 2026
For decades, families facing severe traumatic brain injury have lived with a painful assumption: once brain tissue is lost, recovery is limited to what the surviving brain can re-learn. Rehabilitation can help. Technology can assist. Time can produce surprises. But the central wound—the loss of brain cells, circuits, and connections—has often been treated as permanent. That assumption is beginning to change.